The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Real-world comparison of D-RVd and RVd induction in patients with newly diagnosed multiple myeloma
Nisha Joseph, MD, Winship Cancer Institute, Emory University, Atlanta, GA, discusses an analysis of real-world data comparing the responses and survival outcomes in standard- and high-risk newly diagnosed transplant-eligible patients with multiple myeloma (MM) who received an induction regimen of daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVd) or RVd prior to transplantation. Adding daratumumab to the RVd regimen confers a benefit to depth of response, and early follow-up data suggest a positive impact on progression-free survival (PFS) and overall survival (OS) with D-RVd in both standard- and high-risk patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Janssen Oncology
Honoraria: BMS
